![]() |
Name |
Bulnesene
|
Molecular Formula | C15H26 | |
IUPAC Name* |
(3S,3aS,5R)-3,8-dimethyl-5-propan-2-yl-1,2,3,3a,4,5,6,7-octahydroazulene
|
|
SMILES |
C[C@H]1CCC2=C(CC[C@H](C[C@@H]12)C(C)C)C
|
|
InChI |
InChI=1S/C15H26/c1-10(2)13-7-5-11(3)14-8-6-12(4)15(14)9-13/h10,12-13,15H,5-9H2,1-4H3/t12-,13+,15-/m0/s1
|
|
InChIKey |
AAPYGFMEZRXPJI-GUTXKFCHSA-N
|
|
Synonyms |
bulnesene
|
|
CAS | NA | |
PubChem CID | 16679399 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 206.37 | ALogp: | 4.7 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.517 |
Caco-2 Permeability: | -4.518 | MDCK Permeability: | 0.00001580 |
Pgp-inhibitor: | 0.427 | Pgp-substrate: | 0.007 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.977 |
30% Bioavailability (F30%): | 0.703 |
Blood-Brain-Barrier Penetration (BBB): | 0.327 | Plasma Protein Binding (PPB): | 97.10% |
Volume Distribution (VD): | 5.125 | Fu: | 1.72% |
CYP1A2-inhibitor: | 0.497 | CYP1A2-substrate: | 0.714 |
CYP2C19-inhibitor: | 0.327 | CYP2C19-substrate: | 0.914 |
CYP2C9-inhibitor: | 0.621 | CYP2C9-substrate: | 0.652 |
CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.173 |
CYP3A4-inhibitor: | 0.47 | CYP3A4-substrate: | 0.511 |
Clearance (CL): | 11.511 | Half-life (T1/2): | 0.091 |
hERG Blockers: | 0.032 | Human Hepatotoxicity (H-HT): | 0.06 |
Drug-inuced Liver Injury (DILI): | 0.838 | AMES Toxicity: | 0.016 |
Rat Oral Acute Toxicity: | 0.022 | Maximum Recommended Daily Dose: | 0.022 |
Skin Sensitization: | 0.781 | Carcinogencity: | 0.443 |
Eye Corrosion: | 0.963 | Eye Irritation: | 0.983 |
Respiratory Toxicity: | 0.129 |